Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Interest & Investment Income (2016 - 2026)

Anika Therapeutics has reported Interest & Investment Income over the past 17 years, most recently at $667000.0 for Q1 2026.

  • Quarterly Interest & Investment Income rose 60.72% to $667000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Mar 2026, down 7.59% year-over-year, with the annual reading at $1.7 million for FY2025, 25.37% down from the prior year.
  • Interest & Investment Income was $667000.0 for Q1 2026 at Anika Therapeutics, up from $118000.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $997000.0 in Q3 2025 and troughed at -$154000.0 in Q1 2022.
  • The 5-year median for Interest & Investment Income is $539000.0 (2023), against an average of $453764.7.
  • The largest YoY upside for Interest & Investment Income was 1008.33% in 2022 against a maximum downside of 258.14% in 2022.
  • A 5-year view of Interest & Investment Income shows it stood at $276000.0 in 2022, then soared by 109.06% to $577000.0 in 2023, then grew by 28.94% to $744000.0 in 2024, then tumbled by 84.14% to $118000.0 in 2025, then surged by 465.25% to $667000.0 in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Interest & Investment Income are $667000.0 (Q1 2026), $118000.0 (Q4 2025), and $997000.0 (Q3 2025).